Treatment of chronic heart failure with β-adrenergic receptor antagonists: A convergence of receptor pharmacology and clinical cardiology

Circulation Research

Volumn 109, Issue 10, 2011, Pages 1176-1194

  Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

blockers; adrenergic receptors; drug development; heart failure; norepinephrine

Indexed keywords

ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOGENIC AMINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NORADRENALIN; PHOSPHODIESTERASE;

CARDIOMYOPATHY; CARDIOTOXICITY; DOWN REGULATION; EUROPE; GENE EXPRESSION; HEART FAILURE; HEART MUSCLE CELL; HEART TRANSPLANTATION; INTRACELLULAR SIGNALING; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; DRUG DISCOVERY; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; MYOCARDIUM; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 80155140409     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.245092     Document Type: Review

References (178)

1. Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1-e194.
2. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol. 1948;153:586-600.
3. Powell CE, Slater IH. Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J Pharmacol Exp Ther. 1958;122: 480-488.
4. Moran NC, Perkins ME. Adrenergic blockade of the mammalian heart by a dichloro analogue of isoproterenol. J Pharmacol Exp Ther. 1958; 124:223-237.
5. Black JW, Crowther AF, Shanks RG, Smith LH, Dorhhorst AC. A new adrenergic beta receptor antagonist. Lancet. 1964 7342:1080-1081.
6. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG Jr. Differentiation of receptor systems activated by sympathomimetic amines. Nature. 1967;214:597-598.
7. Furchgott RF. The pharmacological differentiation of adrenergic receptors. Ann N Y Acad Sci. 1967;139:553-570.
8. Dunlop D, Shanks RG. Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother. 1968;32:201-208.
9. Bristow MR, Sherrod TR, Green RD. Analysis of beta receptor drug interactions in isolated rabbit atrium, aorta, stomach, and trachea. J Pharmacol Exp Ther. 1970;171:52-61.
10. Stiles GL, Taylor S, Lefkowitz RJ. Human cardiac beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Life Sci. 1983;33:467-473. (Pubitemid 13064788)
11. Bristow MR, Ginsburg R: 2 Receptors on myocardial cells in human ventricular myocardium. Am J Cardiol. 1986;57:3F-6F. (Pubitemid 16054089)
12. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB.p1-And 2-adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective 1-receptor downregulation in heart failure. Circ Res. 1986;59:297-309. (Pubitemid 17178124)
13. Ziegler K. Uber die wirkung intravenöser adrenalininjektion auf das Gefäßsystem und ihre beziehung zur arteriosklerose. Beitr Pathol Anat. 1905;38:229.
14. Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, Sageman WS, Daniels JR. Anthracycline-associated cardiac and renal damage in rabbits: evidence for mediation by vasoactive substances. Lab Invest. 1981;45:157-168. (Pubitemid 11012888)
15. Bristow MR, Kantrowitz NE, Harrison WD, Minobe WA, Sageman WS, Billingham ME. Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiovasc Pharmacol. 1983;5: 913-919. (Pubitemid 14234335)
16. Deisher TA, Ginsburg R, Fowler MB, Billingham ME, Bristow MR. Spontaneous reversibility of catecholamine-induced cardiotoxicity in rats. Am J Cardiovasc Pathol. 1995;5:79-88.
17. Levitzki A, Atlas D, Steer ML. The binding characteristics and number of beta-adrenergic receptors on the turkey erythrocyte. Proc Natl Acad Sci. 1974;71:2773-2776.
18. Lefkowitz RJ, Mukherjee C, Coverstone M, Caron MG. Stereospecific (3H)(minus)-alprenolol binding sites, beta-adrenergic receptors and adenylate cyclase. Biochem Biophys Res Commun. 1974;60:703-709.
19. Aurbach GD, Fedak SA, Woodard CJ, Palmer JS, Hauser D, Troxler F. Beta-adrenergic receptor: stereospecific interaction of iodinated betablocking agent with high affinity site. Science. 1974;186:1223-1224.
20. Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl J Med. 1962;267:650-654.
21. Chidsey CA, Braunwald E, Morrow AG. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med. 1965;39:442-451.
22. Chidsey CA, Sonnenblick EH, Morrow AG, Braunwald E. Norepinephrine stores and contractile force of papillary muscle from the failing human heart. Circulation. 1966;33:43-51.
23. Gaffney TE, Braunwald E. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med. 1963;34:320-324.
24. Epstein SE, Braunwald E. The effect of beta adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease. Ann Intern Med. 1966;65:20-27.
25. Karliner JS, Barnes P, Brown M, Dollery C. Chronic heart failure in the guinea pig increases cardiac alpha 1-and beta-adrenoceptors. Eur J Pharmacol. 1980;67:115-118. (Pubitemid 10018672)
26. Colucci WS, Alexander RW, Williams GH, Rude RE, Holman BL, Konstam MA, Wynne J, Mudge GH Jr, Braunwald E. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981;305:185-190. (Pubitemid 11040736)
27. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978;41:233-243. (Pubitemid 8318642)
28. Bristow MR, Ginsburg R, Minobe WA, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and A-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211. (Pubitemid 12079105)
29. Swedberg K, Viquerat C, Rouleau JL Roizen M, Atherton B, Parmley WW, Chatterjee K. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without heart failure. Am J Cardiol. 1984;54:783-786. (Pubitemid 14006148)
30. Rose CP, Burgess JH, Cousineau D. Tracer norepinephrine kinetics in coronary circulation of patients with heart failure secondary to chronic pressure and volume overload. J Clin Invest. 1985;76:1740-1747. (Pubitemid 16196040)
31. Hasking GJ, Esler MD, Jennings GL, Burton D, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-621. (Pubitemid 16081418)
32. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. Am J Cardiol. 1997;80:7L-14L. (Pubitemid 27528443)
33. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311: 819-823. (Pubitemid 14035089)
34. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the A-adrenergic receptor pathway in the intact failing human heart: progressive receptor downregulation and subsensitivity to agonist response. Circulation. 1986;74:1290-1302. (Pubitemid 17189248)
35. Bristow MR. The adrenergic nervous system in heart failure. N Engl J Med. 1984;31:850-851. (Pubitemid 14035095)
36. Fowler MB, Bristow MR. Rationale for beta-adrenergic blocking drugs in cardiomyopathy. Am J Cardiol. 1985;55:D120-D124.
37. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beat-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022-1036.
38. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1979;1:1374-1376. (Pubitemid 9204152)
39. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996;17(Suppl B):8-16. (Pubitemid 26136854)
40. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J. 1980;44:117-1133.
41. Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet. 1981;2:490-493. (Pubitemid 11051464)
42. Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL, Bartholomew M. A randomized trial of low-dose betablockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1985;55:471-475. (Pubitemid 15173090)
43. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985;72:536-546. (Pubitemid 15242247)
44. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 1993;71:12C-22C. (Pubitemid 23092238)
45. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased C-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79: 483-490. (Pubitemid 19087699)
46. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson Å, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446. (Pubitemid 24000287)
47. Andersson B, for The Metoprolol in Dilated Cardiomyopathy Trial Study G. Three-year follow-up of patients randomised in the Metoprolol in Dilated Cardiomyopathy trial. Lancet. 1998;351:1180-1181. (Pubitemid 28171830)
48. Brodde OE, Karad K, Zerkowski HR, Rohm N, Reidemeister JC. Coexistence of beta 1-and beta 2-adrenoceptors in human right atrium: direct identification by (f/r)-[125I]iodocyanopindolol binding. Circ Res. 1983;53:752-758. (Pubitemid 14219937)
49. Robberecht P, Delhaye M, Taton G, De Neef P, Waelbroeck M, De Smet JM, Leclerc JL, Chatelain P, Christophe J. The human heart betaadrenergic receptors, I: heterogeneity of the binding sites: presence of 50% beta 1-and 50% beta 2-adrenergic receptors. Mol Pharmacol. 1983;24:169-173. (Pubitemid 13004118)
50. Vago T, Bevilacqua M, Dagani R, Meroni R, Frigeni G, Santoliss C, Norbiato G. Comparison of rat and human left ventricle beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Biochem Biophys Res Commun. 1984;121:346-354. (Pubitemid 14117159)
51. Waelbroeck M, Taton G, Delhaye M, Chatelain P, Camus JC, Pochet R, Leclerc JL, De Smet JM, Robberecht P, Christophe J. The human heart beta-adrenergic receptors, II: coupling of beta 2-adrenergic receptors with the adenylate cyclase system. Mol Pharmacol. 1983;24:174-182. (Pubitemid 13004119)
52. Wilson C, Lincoln C. Beta-adrenoceptor subtypes in human, rat, guinea pig, and rabbit atria. J Cardiovasc Pharmacol. 1984;6:1216-1221. (Pubitemid 15193281)
53. Ask JA, Stene-Larsen G, Helle KB, Resch F. Functional beta 1-and beta 2-adrenoceptors in the human myocardium. Acta Physiol Scand. 1985; 123:81-88. (Pubitemid 15155509)
54. Zerkowski HR, Ikezono K, Rohm N, Reidemeister JC, Brodde OE. Human myocardial beta-adrenoceptors: demonstration of both beta 1-and beta 2-adrenoceptors mediating contractile responses to betaagonists on the isolated right atrium. Naunyn Schmiedebergs Arch Pharmacol. 1986;332:142-147. (Pubitemid 16134501)
55. Brodde OE, Schüler S, Kretsch R, Brinkmann M, Borst HG, Hetzer R, Reidemeister JC, Warnecke H, Zerkowski HR. Regional distribution of beta-adrenoceptors in the human heart: coexistence of functional beta 1-and beta 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol. 1986;8:1235-1242. (Pubitemid 17211590)
56. Bristow MR, Hershberger RE, Port JD, Minobe W, Rasmussen R.p1-And 2-adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharm. 1989;35:295-303. (Pubitemid 19090345)
57. Brodde OE, O'Hara N, Zerkowski HR, Rohm N. Human cardiac betaadrenoceptors: both beta 1-and beta 2-adrenoceptors are functionally coupled to the adenylate cyclase in right atrium. J Cardiovasc Pharmacol. 1984;6:1184-1191. (Pubitemid 15193277)
58. Brown JE, McLeod AA, Shand DG. Evidence for cardiac beta 2-adrenoceptors in man. Clin Pharmacol Ther. 1983;33:424-428. (Pubitemid 13093760)
59. Arnold JM, O'Connor PC, Riddell JG, Harron DW, Shanks RG, McDevitt DG. Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol. 1985;19:619-630. (Pubitemid 16255932)
60. Mettauer B, Rouleau JL, Burgess JH. Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure. Am Heart J. 1985;109:840-847. (Pubitemid 15118458)
61. Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, Johnson TD, Bond RA, Lefkowitz RJ. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science. 1994;264:582-586.
62. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 1997;79:794-798. (Pubitemid 27152342)
63. Stephen SA. Unwanted effects of propranolol. Am J Cardiol. 1966;18: 463-472.
64. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Long-term C-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990;88:223-229. (Pubitemid 20100367)
65. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol. 1990; 66:603-607. (Pubitemid 20292518)
66. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991; 84:2426-2441.
67. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators. Dose-response of chroniCk-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642. (Pubitemid 24114241)
68. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24: 1678-1687. (Pubitemid 24369193)
69. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
70. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD Levin HR, Neuberg GW, DeLong G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92:1499-1506.
71. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 1995; 92:212-218.
72. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebocontrolled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 1996;94: 2793-2799. (Pubitemid 26411743)
73. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94: 2807-2816. (Pubitemid 26411745)
74. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure: US Carvedilol Heart Failure Study Group. Circulation. 1996;94: 2800-2806. (Pubitemid 26411744)
75. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA. Safety and efficacy of carvedilol in severe heart failure: the US Carvedilol Heart Failure Study Group. J Card Fail. 1997;3: 173-179. (Pubitemid 127674849)
76. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355. (Pubitemid 26152713)
77. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-225. (Pubitemid 40222359)
78. BEST Trial Investigators. A trial of the beta-adrenergic blocker bucindolol in patients with advanced heart failure. N Engl J Med. 2001;344:1659-1667.
79. CIBIS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
80. MERIT Steering Committee and Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001-2007.
81. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658. (Pubitemid 32479962)
82. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR; BEST Investigators. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42:914-922. (Pubitemid 37059754)
83. CIBIS Investigators and Committees. A randomized trial of betablockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
84. Domanski MJ, Krause-Steinrauf H, Massie BM, Deedwania P, Follmann D, Kovar D, Murray D, Oren R, Rosenberg Y, Young J, Zile M, Eichhorn E; BEST Investigators. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003;9: 354-363. (Pubitemid 37351802)
85. O'Connor CM, Fiuzat M, Caron MF, Davis G, Karl Swedberg K, Peter E. Carson PE, Koch B, Bristow MR. Influence of global region on outcomes in large heart failure C-blocker trials. J Am Coll Cardiol. 2011;58:915-922.
86. Anand I, Fiuzat M, O'Connor C, Lindenfeld J, Carson P, Udelson J, Eric Eichhorn E, Domanski M, Davis G, Bristow MR. Impact of baseline volume status and LVEF on all-cause mortality in the BEST Trial. J Am Coll Cardiol. 2010;55:A37.
87. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13. (Pubitemid 36835815)
88. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94: 2817-2825. (Pubitemid 26411746)
89. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546-551. (Pubitemid 30642529)
90. Bristow MR, Feldman AM, Adams KF, Goldstein S. Selective versus nonselective-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J Cardiac Fail. 2003;9:444-453. (Pubitemid 38055651)
91. Brodde OE, Daul A, Wellstein A, Palm D, Michel MC, Beckeringh JJ. Differentiation of beta 1-and beta 2-adrenoceptor-mediated effects in humans. Am J Physiol. 1988;254:H199-H206.
92. Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE; REVERT Study Group. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation. 2007;116: 49-56. (Pubitemid 47016246)
93. Mann DL, Kent RL, Parsons B, Cooper GIV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85: 790-804.
94. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)-and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 1999;100: 2210-2212.
95. Sucharov CC, Mariner PD, Nunley KR, Long CS, Leinwand LA, Bristow MR. Ap1-adrenergic receptor, CaM Kinase II dependent pathway mediates cardiac myocyte fetal gene induction. Am J Physiol Heart Circ Physiol. 2006;291:H1299-H1308. (Pubitemid 44343675)
96. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, Yatani A, Dorn GW II. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 2000;101:1707-1714. (Pubitemid 30196632)
97. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci. 1999;96:7059-7064. (Pubitemid 29275009)
98. Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, Sastravaha A, Roden RL, Asano K, Blaxall BC, Wu SC, Communal C, Singh K, Colucci WS, Bristow MR, Port JD. Myocardial-directed overexpression of the humanp1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817-830. (Pubitemid 30658918)
99. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW, Liggett SB. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9:1300-1305. (Pubitemid 37279854)
100. Dorn GW II, Tepe NM, Lorenz JN, Koch WJ, Liggett SB. Low-and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaqoverexpressing mice. Proc Natl Acad Sci. 1999;96:6400-6405. (Pubitemid 29256677)
101. Freeman K, Lerman I, Kranias EG, Bohlmeyer T, Bristow MR, Lefkowitz RJ, Iaccariono G, Koch WJ, Leinwand LA. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest. 2001;107:967-974. (Pubitemid 32323407)
102. Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, Kobilka BK. Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc Natl Acad Sci. 1987;84:7920-7924. (Pubitemid 17162813)
103. Dixon RA, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, Frielle T, Bolanowski MA, Bennett CD, Rands E, Diehl RE, Mumford RA, Slater EE, Sigal IS, Caron MG, Lefkowitz RJ, Strader CD. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature. 1986;321:75-79. (Pubitemid 16080889)
104. Frielle T, Caron MG, Lefkowitz RJ. Properties of the beta 1-and beta 2-adrenergic receptor subtypes revealed by molecular cloning. Clin Chem. 1989;35:721-725. (Pubitemid 19162062)
105. Xiao RP, Ji X, Lakatta EG. Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol. 1995;47:322-329.
106. Heubach JF, Graf EM, Molenaar P, Jäger A, Schröder F, Herzig S, Harding SE, Ravens U. Murine ventricular L-type Ca(2f) current is enhanced by zinterol via beta(1)-adrenoceptors, and is reduced in TG4 mice overexpressing the human beta(2)-adrenoceptor. Br J Pharmacol. 2001;133:73-82. (Pubitemid 32500453)
107. Ahmet I, Krawczyk M, Zhu W, Woo AY, Morrell C, Poosala S, Xiao RP, Lakatta EG, Talan MI. Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction. J Pharmacol Exp Ther. 2008;325:491-499. (Pubitemid 351574789)
108. Witchitz S, Cohen-Solal A, Dartois N, Weisslinger N, Juste K, Darmon JY. Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. Am J Cardiol. 2000; 85:1467-1471. (Pubitemid 30336584)
109. Newton GE, Parker JD. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 1996;94:353-538.
110. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang Cheng-Seng, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Domanski MJ, Eichhorn EJ, Lavori P, Zelis R. Effect of baseline or changes in adrenergic activity on clinical outcomes in the Beta-Blocker Evaluation of Survival Trial (BEST). Circulation. 2004;110:1437-1442. (Pubitemid 39242692)
111. Colucci WS, Williams GH, Braunwald E. Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure. Ann Intern Med. 1980;93:452-453. (Pubitemid 10055910)
112. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R, Kelly S, Newton GE, Floras JS, Parker JD. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation. 2001;104: 2194-2199. (Pubitemid 33043299)
113. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002;346: 1357-1365. (Pubitemid 34754608)
114. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, Liggett SB. An2C-adrenergic receptor polymorphism alters the norepinephrine lowering effects and therapeutic response of the beta blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010;3:21-28.
115. O'Connor C, Anand I, Fiuzat M, Plehn J, Gottlieb S, Silver M, Lindenfeld J, Miller A, White M, Liggett S, Davis G, Robertson A, Bristow MR, Carson P. Additive effects of 1 389 Arg/Gly2C 322-325 Wt/Del adrenergic receptor genotype combinations on adjudicated hospitalizations and death in the BEST trial. J Cardiac Fail. 2008;14:S69.
116. Buxton IL, Brunton LL. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem. 1983;258: 10233-10239. (Pubitemid 14241179)
117. Dodge-Kafka KL, Langeberg L, Scott JD. Compartmentation of cyclic nucleotide signaling in the heart: the role of A-kinase anchoring proteins. Circ Res. 2006;98:993-1001.
118. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science. 2002; 295:1711-1715. (Pubitemid 34202906)
119. Lygren B, Carlson CR, Santamaria K, Lissandron V, McSorley T, Litzenberg J, Lorenz D, Wiesner B, Rosenthal W, Zaccolo M, Taskén K, Klussmann E. AKAP complex regulates Ca2fre-uptake into heart sarcoplasmic reticulum. EMBO Rep. 2007;8:1061-1067. (Pubitemid 350042342)
120. Lowes BD, Shakar S, Gerber M, J Liard J-F, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, David DeMets D, Bristow MR. Rationale and design of the Enoximone Clinical Trials Program. J Cardiac Fail. 2005;11:659-669. (Pubitemid 41797494)
121. Schwinger RH, Bölck B, Münch G, Brixius K, Müller-Ehmsen J, Erdmann E. cAMP-dependent protein kinase A-stimulated sarcoplasmic reticulum function in heart failure. Ann N Y Acad Sci. 1998;853: 240-250.
122. Metra M, Eichhorn E, Abraham WT, Linseman J, Böhm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR; for the ESSENTIAL Investigators. Effects of low-dose oral enoximone administration on mortality, morbidity and exercise capacity in patients with advanced heart failure: the randomised, double-blind, placebo-controlled, parallel group ESSENTIAL Trials. Eur Heart J. 2009;30:3015-3026.
123. Zhu WZ, Wang SQ, Chakir K, Yang D, Zhang T, Brown JH, Devic E, Kobilka BK, Cheng H, Xiao RP. Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2f/calmodulin kinase II. J Clin Invest. 2003;111: 617-625. (Pubitemid 36278580)
124. Kirchhefer U, Schmitz W, Scholz H, Neumann J. Activity of cAMPdependent protein kinase and Ca2f/calmodulin-dependent protein kinase in failing and nonfailing human hearts. Cardiovasc Res. 1999; 42:254-261. (Pubitemid 29167092)
125. Bossuyt J, Helmstadter K, Wu X, Clements-Jewery H, Haworth RS, Avkiran M, Martin JL, Pogwizd SM, Bers DM. Ca2f/calmodulindependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ Res. 2008;102:695-702. (Pubitemid 351457864)
126. Calalb MB, McKinsey TA, Newkirk S, Bohlmeyer T, Huynh K, Sucharov CC, Bristow MR. Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart. Clin Transl Sci. 2009;2:325-332.
127. Wang W, Zhu W, Wang S, Yang D, Crow MT, Xiao RP, Cheng H. Sustained beta1-adrenergic stimulation modulates cardiac contractility by Ca2f/calmodulin kinase signaling pathway. Circ Res. 2004;95: 798-806. (Pubitemid 39390582)
128. Anderson ME. CaMKII and a failing strategy for growth in heart. J Clin Invest. 2009;119:1082-1085.
129. Grimm M, Brown JH. Beta-adrenergic receptor signaling in the heart: role of CaMKII. J Mol Cell Cardiol. 2010;48:322-330.
130. Takahashi T, Tang T, Lai NC, Roth DM, Rebolledo B, Saito M, Lew WY, Clopton P, Hammond HK. Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation. 2006;114:388-396. (Pubitemid 44264820)
131. Fentzke RC, Korcarz CE, Lang RM, Lin H, Leiden JM. Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J Clin Invest. 1998;101:2415-2426. (Pubitemid 28270436)
132. Sucharov CC, Dockstader K, Nunley K, McKinsey TA, Bristow M. C-Adrenergic receptor stimulation and activation of PKA protect againstp1-adrenergic mediated phosphorylation of PKD and HDAC5. J Card Fail. 2011;17:592-600.
133. Antos CL, Frey N, Marx SO, Reiken S, Gaburjakova M, Richardson JA, Marks AR, Olson EN. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res. 2001;89:997-1004. (Pubitemid 34640866)
134. Lubbe WF, Podzuweit T, Daries PS, Opie LH. The role of cyclic adenosine monophosphate in adrenergic effects on ventricular vulnerability to fibrillation in the isolated perfused rat heart. J Clin Invest. 1978;61:1260-1269. (Pubitemid 8324150)
135. Ungerer M, Böhm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation. 1993;87:454-463. (Pubitemid 23040915)
136. Bristow MR, Minobe W, Raynolds, MV Port JD, Rasmussen R, Ray PE, Feldman AM. Reducedp1 receptor messenger RNA abundance in the failing human heart. J Clin Invest. 1993;92:2737-2745.
137. Mitchusson KD, Blaxall BC, Pende A, and Port JD. Agonist-mediated destabilization of humanp1-adrenergic receptor mRNA; role of the 3f untranslated region. Biochem Biophys Res Comm. 1998;252:357-362. (Pubitemid 28542891)
138. Dunigan CD, Hoang Q, Curran PK, Fishman PH. Complexity of agonist-and cyclic AMP-mediated downregulation of the human beta 1-adrenergic receptor: role of internalization, degradation, and mRNA destabilization. Biochemistry. 2002;41:8019-8030. (Pubitemid 34655169)
139. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:1024-1039.
140. Freedman NJ, Liggett SB, Drachman DE, Pei G, Caron MG, Lefkowitz RJ. Phosphorylation and desensitization of the human beta 1-adrenergic receptor: involvement of G protein-coupled receptor kinases and cAMPdependent protein kinase. J Biol Chem. 1995;270:17953-17961.
141. Kunapuli P, Onorato JJ, Hosey MM, Benovic JL. Expression, purification, and characterization of the G protein-coupled receptor kinase GRK5. J Biol Chem. 1994;269:1099-1105. (Pubitemid 24032491)
142. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, Van Dop C. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest. 1988;82:189-197. (Pubitemid 18262515)
143. Neumann J, Schmitz W, Scholz H, von Meyerinck L, Döring V, Kalmar P. Increase in myocardial Gi-proteins in heart failure. Lancet. 1988;2: 936-937.
144. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, Koch WJ. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation. 2009;119: 89-98.
145. Casey LM, Pistner AR, Belmonte SL, Migdalovich D, Stolpnik O, Nwakanma FE, Vorobiof G, Dunaevsky O, Matavel A, Lopes CM, Smrcka AV, Blaxall BC. Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. Circ Res. 2010;107: 532-539.
146. Baker JG, Hall IP, Hill SJ. Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol. 2003;64:1357-1369. (Pubitemid 37532226)
147. Galandrin S, Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006;70:1575-1584.
148. Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD, Rockman HA. Beta-blockers alprenolol and carvedilol stimulate betaarrestin-mediated EGFR transactivation. Proc Natl Acad Sci. 2008;105: 14555-14560.
149. Purcell NH, Wilkins BJ, York A, Saba-El-Leil MK, Meloche S, Robbins J, Molkentin JD. Genetic inhibition of cardiac ERK1/2 promotes stressinduced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci. 2007;104:14074-14079. (Pubitemid 350003337)
150. Yeh JL, Hsu JH, Wu PJ, Liou SF, Liu CP, Chen IJ, Wu BN, Dai ZK, Wu JR. KMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathways. Br J Pharmacol. 2010;159:1151-1160.
151. Strosberg AD. Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol. 1997;37:421-450. (Pubitemid 27238883)
152. Trochu JN, Leblais V, Rautureau Y, Bévérelli F, Le Marec H, Berdeaux A, Gauthier C. Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol. 1999;128:69-76. (Pubitemid 29425269)
153. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, Balligand JL, Le Marec H. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest. 1998;102: 1377-1384. (Pubitemid 28467566)
154. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation. 2001; 103:1649-1655. (Pubitemid 32246612)
155. Moens AL, Leyton-Mange JS, Niu X, Yang R, Cingolani O, Arkenbout EK, Champion HC, Bedja D, Gabrielson KL, Chen J, Xia Y, Hale AB, Channon KM, Halushka MK, Barker N, Wuyts FL, Kaminski PM, Wolin MS, Kass DA, Barouch LA. Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor. J Mol Cell Cardiol. 2009;47:576-585.
156. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
157. Mason RP, Kubant R, Jacob RF, Jacoby AM, Port JD, Bristow MR, Malinski T. Effect of the A3-receptor antagonist SR59230A on bucindolol-induced release of nitric oxide and peroxynitrite from human endothelium. J Cardiac Fail. 2008;14:S76.
158. Taylor MRG, Bristow MR. The emerging pharmacogenomics of the beta-adrenergic receptors. Congestive Heart Fail. 2004;10:281-288.
159. Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, Liggett SB. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci. 1996;93:10483-10488.
160. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999;274:12670-12674.
161. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a highly conservedp1-adrenergic receptor motif alters C-blocker response in multiple models and human heart failure. Proc Natl Acad Sci USA. 2006;103: 11288-11293. (Pubitemid 44156511)
162. Sandilands AJ, O'Shaughnessy KM, Brown MJ. Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389p1-adrenoceptors versus Gly389p1-adrenoceptors in isolated human atrial myocardium. Br J Pharmacol. 2003;138:386-392. (Pubitemid 36188600)
163. White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R, Ball SG, Hall AS, Balmforth AJ. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail. 2003;5:463-468. (Pubitemid 37021640)
164. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B, Muhlestein JB, Donahue M, Liggett SB, Anderson JL, Kraus WE. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol. 2008;52:644-651.
165. Metra M, Bristow MR. Beta-blocker therapy in chronic heart failure. In: Mann DL, ed. Heart Failure: A Companion to Braunwald's Heart Disease. Phailadelphia, PA: WB Saunders; 2010.
166. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. C-Adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 1985;17:41-52. (Pubitemid 15070412)
167. Bristow MR, Taylor MRG. Alterations in myocardial gene expression as a basis for cardiomyopathies and heart failure. In: Heart failure: molecules, mechanisms and therapeutic targets. Novartis Found Symposium. 2006:73-83.
168. Eichhorn EJ, Bristow MR. Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation. 1996;94:2285-2296. (Pubitemid 26360526)
169. Feldman AM, Ray PE, Silan CM, Mercer JA, Minobe W, Bristow MR. Selective gene expression in failing human heart: quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation. 1991;83:1866-1872.
170. Abraham WT, Gilbert EM, Lowes BD, Minobe WA, Larrabee P, Roden RL, Dutcher D, Sederberg J, Lindenfeld JA, Wolfel EE, Shakar SF, Ferguson D, Volkman K, Quaife RA, Robertson AD, Bristow MR. Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med. 2002;8:750-760. (Pubitemid 36337501)
171. Pandya K, Porter K, Rockman HA, Smithies O. Decreased betaadrenergic responsiveness following hypertrophy occurs only in cardiomyocytes that also re-express beta-myosin heavy chain. Eur J Heart Fail. 2009;11:648-652.
172. Panchal AR, Stanley WC, Kerner J, Sabbah HN. Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J Card Fail. 1998;4:121-126. (Pubitemid 28381150)
173. Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, Mule JD, Vered Z, Lahiri A. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet. 2003; 362:14-21. (Pubitemid 36840896)
174. Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol. 1992;19:1622-16233.
175. Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J. 2007;28:457-462. (Pubitemid 47343566)
176. Berger R, Strecker K, Hülsmann M, Frey B, Pacher R, Stanek B. Experience with beta-blocker therapy in patients with advanced heart failure evaluated for HTx. J Heart Lung Transplant. 2000;19: 1081-1088.
177. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1-6.
178. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659-667. (Pubitemid 38043972)